Featured Research

from universities, journals, and other organizations

Novel genetic mutation that causes the most common form of eye cancer discovered

Date:
November 18, 2010
Source:
Memorial Sloan-Kettering Cancer Center
Summary:
A new study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer.

An international, multi-center study has revealed the discovery of a novel oncogene that is associated with uveal melanoma, the most common form of eye cancer. Researchers have isolated an oncogene called GNA11 and have found that it is present in more than 40 percent of tumor samples taken from patients with uveal melanoma.

The findings are being published early online November 17, 2010 in the New England Journal of Medicine and will appear in the December 2, 2010, print issue.

"These findings are significant because we now have a much better understanding of the precise mechanism of this disease, which may yield targets and treatments in the future, said Boris C. Bastian, MD, PhD, Chair of the Department of Pathology at Memorial Sloan-Kettering Cancer Center and senior author of the study. "Currently, once this type of melanoma has spread beyond the eye, therapeutic options are extremely limited," added Dr. Bastian.

The eye is the second most common site in the body for melanomas, after the skin. There are about 1,500 people diagnosed with melanoma of the eye in the US each year. Most frequently, melanomas of the eye occur in the part of the eye known as the uveal tract -- the vascular layer that includes the iris (the pigmented cells surrounding the pupil), the ciliary body (the ring-shaped muscle that changes the size of the pupil and the shape of the lens when the eye focuses), and the choroid (the pigmented layer under the retina). Most patients with melanoma of the eye experience no symptoms until the tumor has become large enough to cause vision problems. In this study, DNA was extracted from tumor samples of patients and genetic sequencing was performed. To validate this new oncogene, immunocompromised mice were injected with cells engineered to harbor the mutated genes and monitored for the formation of tumors.

Previous studies from this group have revealed another oncogene associated with uveal melanoma, called GNAQ. Prior to the discovery of GNAQ and GNA11, genetic mutations responsible for uveal melanoma were completely unknown. Based on this latest research and recent studies, 83 percent of uveal melanomas are now known to have an active mutation in the GNAQ or GNA11 oncogenes.

In addition, said Dr. Bastian, "since the large majority of uveal melanomas harbor mutations in these two oncogenes, this suggests that the activation of the Gq/11 pathway is the main route to the development of uveal melanoma and identifies a brand new target for therapeutic intervention."


Story Source:

The above story is based on materials provided by Memorial Sloan-Kettering Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Catherine D. Van Raamsdonk et al. Mutations in GNA11 in Uveal Melanoma. New England Journal of Medicine, November 17, 2010 DOI: 10.1056/NEJMoa1000584

Cite This Page:

Memorial Sloan-Kettering Cancer Center. "Novel genetic mutation that causes the most common form of eye cancer discovered." ScienceDaily. ScienceDaily, 18 November 2010. <www.sciencedaily.com/releases/2010/11/101117184353.htm>.
Memorial Sloan-Kettering Cancer Center. (2010, November 18). Novel genetic mutation that causes the most common form of eye cancer discovered. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2010/11/101117184353.htm
Memorial Sloan-Kettering Cancer Center. "Novel genetic mutation that causes the most common form of eye cancer discovered." ScienceDaily. www.sciencedaily.com/releases/2010/11/101117184353.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins